No Data
No Data
Maravai (MRVI) Advances in RNA Research With New Collaboration
Maravai LifeSciences’ MRVI business, TriLink BioTechnologies, recently partnered with Johns Hopkins University to significantly enhance research in RNA therapeutics.
Investors Interested In Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Revenues
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales ratios (or "P/S") below 3.4x, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) lo
Maravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Maravai LifeSciences | 10-Q: Quarterly report
Maravai LifeSciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Baird Maintained an Outperform Rating on the Stock and Raised Its Price Target...
Maravai LifeSciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Baird Maintained an Outperform
UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating
Maravai LifeSciences (MRVI) has an average outperform rating and price target range of $6.50 to $15, according to analysts polled by Capital IQ. Price: 9.42, Change: +0.55, Percent Change: +6.20